{'fraction_non_alphanumeric': 0.02669208770257388, 'fraction_numerical': 0.0076263107721639654, 'mean_word_length': 5.862745098039215, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Preoperative β‐cell function in patients with type 2 diabetes is important for the outcome of Roux‐en‐Y gastric bypass surgery

Roux‐en‐Y gastric bypass surgery leads to remission of type 2 diabetes in the majority of patients suffering from the disease. The gut hormone glucagon‐like peptide‐1 is believed to be of major importance for the remission process. The present project demonstrates a marked difference in the chance of remission of type 2 diabetes in patients with low or high preoperative β‐cell function in spite of a similar post‐surgery increase in postprandial glucagon‐like peptide‐1 release. Furthermore, post‐surgery intravenous glucose administration, which does not stimulate release of glucagon‐like peptide‐1, leads to increased insulin secretion in the patients with the best preoperative β‐cell function. Together the present findings indicate that patients with type 2 diabetes with high preoperative β‐cell function experience a glucagon‐like peptide‐1‐independent increase in β‐cell function after gastric bypass surgery.